RPRX Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of -4.76%. Royalty Pharma PLC's return on equity of 11.56% beat Amicus Therapeutics's return on equity of -71.17%.

Royalty Pharma PLC has a consensus price target of $41.53, signalling upside risk potential of 60.71%. On the other hand Amicus Therapeutics has an analysts' consensus of $17.33 which suggests that it could grow by 86.38%. Given that Amicus Therapeutics has higher upside potential than Royalty Pharma PLC, analysts believe Amicus Therapeutics is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.193%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 3.25%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are larger than Amicus Therapeutics quarterly revenues of $141.5M. Royalty Pharma PLC's net income of $544M is higher than Amicus Therapeutics's net income of -$6.7M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 10.13x while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 6.80x versus 5.71x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of -93.55%. Royalty Pharma PLC's return on equity of 11.56% beat Geron's return on equity of -67.86%.

Royalty Pharma PLC has a consensus price target of $41.53, signalling upside risk potential of 60.71%. On the other hand Geron has an analysts' consensus of $7.61 which suggests that it could grow by 113.2%. Given that Geron has higher upside potential than Royalty Pharma PLC, analysts believe Geron is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron has a beta of 0.551, suggesting its less volatile than the S&P 500 by 44.885%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 3.25%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Geron pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are larger than Geron quarterly revenues of $28.3M. Royalty Pharma PLC's net income of $544M is higher than Geron's net income of -$26.4M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 10.13x while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 6.80x versus 76.14x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of -104.98%. Royalty Pharma PLC's return on equity of 11.56% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Royalty Pharma PLC has a consensus price target of $41.53, signalling upside risk potential of 60.71%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 76.27%. Given that Ionis Pharmaceuticals has higher upside potential than Royalty Pharma PLC, analysts believe Ionis Pharmaceuticals is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.485%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 3.25%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are larger than Ionis Pharmaceuticals quarterly revenues of $133.8M. Royalty Pharma PLC's net income of $544M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 10.13x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 6.80x versus 6.33x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 96.33% compared to Royalty Pharma PLC's net margin of 36.03%. Royalty Pharma PLC's return on equity of 11.56% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Royalty Pharma PLC has a consensus price target of $41.53, signalling upside risk potential of 60.71%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,063.08 which suggests that it could grow by 46.64%. Given that Royalty Pharma PLC has higher upside potential than Regeneron Pharmaceuticals, analysts believe Royalty Pharma PLC is more attractive than Regeneron Pharmaceuticals.

Royalty Pharma PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Royalty Pharma PLC has a quarterly dividend of $0.21 per share corresponding to a yield of 3.25%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 31.58% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $564.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Royalty Pharma PLC's net income of $544M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Royalty Pharma PLC's price-to-earnings ratio is 10.13x while Regeneron Pharmaceuticals's PE ratio is 17.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 6.80x versus 5.97x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.